Usefulness of administration of non-organophosphate cholinesterase inhibitors before acute exposure to organophosphates: Assessment using paraoxon

Journal of Applied Toxicology

Volumn 33, Issue 9, 2013, Pages 894-900

  Petroianu, Georg A ^a,b   Nurulain, Syed M ^b   Shafiullah, Mohamed ^b   Hasan, Mohamed Y ^b   Kuča, Kamil ^c   Lorke, Dietrich E ^a,b  

^a FLORIDA INTERNATIONAL UNIVERSITY   (United States)

^b UNITED ARAB EMIRATES UNIVERSITY   (United Arab Emirates)

^c UNIVERSITY OF DEFENCE   (Czech Republic)

Author keywords

Carbamates; Cholinesterase; Cox analysis; Organophosphate; Oximes; Paraoxon; Pre treatment; Rat

Indexed keywords

7 METHOXYTACRINE; AMILORIDE; CHOLINESTERASE INHIBITOR; METHYLENE BLUE; METOCLOPRAMIDE; PARAOXON; PHYSOSTIGMINE; PYRIDOSTIGMINE; RANITIDINE; TACRINE; TIAPRIDE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BLOOD BRAIN BARRIER; CHOLINERGIC TRANSMISSION; CONTROLLED STUDY; DRUG EFFICACY; IN VIVO STUDY; LETHAL DOSE; MALE; MORTALITY; NONHUMAN; PRIORITY JOURNAL; PROPHYLAXIS; RAT; RISK FACTOR; SURVIVAL; TOXICITY;

CARBAMATES; CHOLINESTERASE; COX ANALYSIS; ORGANOPHOSPHATE; OXIMES; PARAOXON; PRE-TREATMENT; RAT;

ANIMALS; CHOLINESTERASE INHIBITORS; DOSE-RESPONSE RELATIONSHIP, DRUG; LETHAL DOSE 50; MALE; ORGANOPHOSPHATE POISONING; OXIMES; PARAOXON; PHYSOSTIGMINE; PYRIDOSTIGMINE BROMIDE; RANITIDINE; RATS; RATS, WISTAR; TACRINE; TIAPRIDE HYDROCHLORIDE;

RATTUS;

EID: 84880703475     PISSN: 0260437X     EISSN: 10991263     Source Type: Journal    
DOI: 10.1002/jat.2760     Document Type: Article

References (47)

1. Albuquerque EX, Pereira EF, Aracava Y, Fawcett WP, Oliveira M, Randall WR, Hamilton TA, Kan RK, Romano JA, Jr, Adler M. 2006. Effective countermeasure against poisoning by organophosphorus insecticides and nerve agents. Proc. Natl. Acad. Sci. U.S.A. 103: 13220-13225.
2. Antonijevic B, Stojiljkovic MP. 2007. Unequal efficacy of pyridinium oximes in acute organophosphate poisoning. Clin. Med. Res. 5: 71-82.
3. Bajgar J. 2004. Organophosphates/nerve agent poisoning: mechanism of action, diagnosis, prophylaxis, and treatment. Adv. Clin. Chem. 38: 151-216.
4. Balali-Mood M, Shariat M. 1998. Treatment of organophosphate poisoning. Experience of nerve agents and acute pesticide poisoning on the effects of oximes. J. Physiol. Paris 92: 375-378.
5. Blomqvist G, Tavitian B, Pappata S, Crouzel C, Jobert A, Doignon I, Di Giamberardino L. 2001. Quantitative measurement of cerebral acetylcholinesterase using. J. Cereb. Blood Flow Metab. 21: 114-131.
6. Chemnitius JM, Haselmeyer KH, Gonska BD, Kreuzer H, Zech R. 1996. Indirect parasympathomimetic activity of metoclopramide: reversible inhibition of cholinesterases from human central nervous system and blood. Pharmacol. Res. 34: 65-72.
7. Cingolani HE, Ennis IL. 2007. Sodium-hydrogen exchanger, cardiac overload, and myocardial hypertrophy. Circulation 115: 1090-1100.
8. Cox DR. 1972. Regression models and life tables. J. R. Stat. Soc. 34: 189-220.
9. Dunn MA, Hackley BE, Sidell FR. 1997. Pretreatment for nerve agent exposure. In Textbook of Military Medicine: Medical Aspects of Chemical & Biological Warfare, Sidell FR, Takafuji ET, Franz DR (eds). Borden Institute, Walter Reed Army Medical Center: Washington, DC; 181-196.
10. Eddleston M, Buckley NA, Eyer P, Dawson AH. 2008. Management of acute organophosphorus pesticide poisoning. Lancet 371: 597-607.
11. FDA. 2003. FDA Approves Pyridostigmine Bromide as Pretreatment Against Nerve Gas. [Online] Available at: http://www.fda.gov/Drugs/EmergencyPreparedness/BioterrorismandDrugPreparedness/ucm130342.htm
12. Ferreri F, Agbokou C, Gauthier S. 2006. Cognitive dysfunctions in schizophrenia: potential benefits of cholinesterase inhibitor adjunctive therapy. J. Psychiatry Neurosci. 31: 369-376.
13. Gales BJ, Gales MA. 2007. Pyridostigmine in the treatment of orthostatic intolerance. Ann. Pharmacother. 41: 314-318.
14. Galli A, Mori F. 1991. Effectiveness of 1, 2, 3, 4-tetrahydro-9-aminoacridine (THA) as a pretreatment drug for protection of mice from acute diisopropylfluorophosphate (DFP) intoxication. Arch. Toxicol. 65: 330-334.
15. Grant SM, Langtry HD, Brogden RN. 1989. Ranitidine. An updated review of its pharmacodynamic and pharmacokinetic properties and therapeutic use in peptic ulcer disease and other allied diseases. Drugs 37: 801-870.
16. Gupta RC. 2006. Classification and uses of organophosphates and carbamates. In Toxicology of Organophosphate and Carbamate Compounds, Gupta RC (ed.). Elsevier Academic Press: Amsterdam; 5-24.
17. Kuca K, Cabal J, Kassa J. 2005. A comparison of the potency of newly developed oximes (K005, K027, K033, K048) and currently used oximes (pralidoxime, obidoxime, HI-6) to reactivate sarin-inhibited rat brain acetylcholinesterase by in vitro methods. J. Toxicol. Environ. Health A 68: 677-686.
18. Kunes M, Svoboda Z, Kvetina J, Herout V, Herink J, Bajgar J. 2005. Intestinal single-pass in situ perfusion technique in rat: the influence of L-carnitine on absorption of 7-methoxytacrine. Biomed. Pap. Med. Fac. Univ. Palacky Olomouc Czech Repub. 149: 433-435.
19. Lallement G, Baille V, Baubichon D, Carpentier P, Collombet JM, Filliat P, Foquin A, Four E, Masqueliez C, Testylier G, Tonduli L, Dorandeu F. 2002. Review of the value of huperzine as pretreatment of organophosphate poisoning. Neurotoxicology 23: 1-5.
20. Lorke DE, Hasan MY, Nurulain SM, Shafiullah M, Kuča K, Petroianu GA. 2011. Pretreatment for acute exposure to diisopropylfluorophosphate (DFP): In vivo efficacy of different acetylcholinesterase inhibitors. J. Appl. Toxicol. 31:: 515-523.
21. Lorke DE, Hasan MY, Arafat K, Kuca K, Musilek K, Schmitt A, Petroianu GA. 2008a. In vitro oxime protection of human red blood cell acetylcholinesterase inhibited by diisopropyl-fluorophosphate. J. Appl. Toxicol. 28: 422-429.
22. Lorke DE, Nurulain SM, Hasan MY, Kuca K, Musilek K, Petroianu GA. 2008b. Eight new bispyridinium oximes in comparison with the conventional oximes pralidoxime and obidoxime: in vivo efficacy to protect from diisopropylfluorophosphate toxicity. J. Appl. Toxicol. 28: 920-928.
23. Lorke DE, Kalasz H, Petroianu GA, Tekes K. 2008c. Entry of oximes into the brain: a review. Curr. Med. Chem. 15: 743-753.
24. Lorke DE, Petroianu GA. 2009. Minireview: does in-vitro testing of oximes help predict their in-vivo action after paraoxon exposure? J. Appl. Toxicol. 29: 459-469.
25. Lorke DE, Hasan MY, Nurulain SM, Sheen R, Kuca K, Petroianu GA. 2007. Entry of two new asymmetric bispyridinium oximes (K-27 and K-48) into the rat brain: comparison with obidoxime. J. Appl. Toxicol. 27: 482-490.
26. Lucic Vrdoljak A, Calic M, Radic B, Berend S, Jun D, Kuca K, Kovarik Z. 2006. Pretreatment with pyridinium oximes improves antidotal therapy against tabun poisoning. Toxicology 228: 41-50.
27. McCauley LA. 2006. Organophosphates and the gulf war syndrome. In Toxicology of Organophosphate and Carbamate Compounds, Gupta RC (ed.). Elsevier Academic Press: Amsterdam; 69-78.
28. Miller SA, Blick DW, Kerenyi SZ, Murphy MR. 1993. Efficacy of physostigmine as a pretreatment for organophosphate poisoning. Pharmacol. Biochem. Behav. 44: 343-347.
29. Nurulain SM, Lorke DE, Hasan MY, Shafiullah M, Kuca K, Musilek K, Petroianu GA. 2009. Efficacy of eight experimental bispyridinium oximes against paraoxon-induced mortality: comparison with the conventional oximes pralidoxime and obidoxime. Neurotox. Res. 16: 60-67.
30. Oz M, Lorke DE, Petroianu GA. 2009. Methylene blue and Alzheimer's disease. Biochem. Pharmacol. 78: 927-932.
31. Petroianu GA, Hasan MY, Nurulain SM, Shafiullah M, Sheen R, Nagelkerke N. 2006a. Ranitidine in acute high-dose organophosphate exposure in rats: effect of the time-point of administration and comparison with pyridostigmine. Basic Clin. Pharmacol. Toxicol. 99: 312-316.
32. Petroianu GA, Kalasz HJ. 2007. Comparison of the ability of oximes to reactivate human RBC cholinesterases inhibited by ethyl- and methyl-paraoxon. Curr. Org. Chem. 11: 1624-1634.
33. Petroianu GA, Hasan MY, Nurulain SM, Arafat K, Sheen R, Nagelkerke N. 2007. Comparison of two pre-exposure treatment regimens in acute organophosphate (paraoxon) poisoning in rats: tiapride vs. pyridostigmine. Toxicol. Appl. Pharmacol. 219: 235-240.
34. Petroianu GA, Hasan MY, Nurulain SM, Arafat K, Shafiullah M, Sheen R. 2006b. Tiapride pre-treatment in acute exposure to paraoxon: comparison of effects of administration at different points-in-time in rats. Mol. Cell. Biochem. 285: 79-86.
35. Pope CN. 2006. Central nervous system effects and neurotoxicity. In Toxicology of Organophosphate and Carbamate Compounds, Gupta RC (ed.). Elsevier Academic Press: Amsterdam; 271-291.
36. Raina P, Santaguida P, Ismaila A, Patterson C, Cowan D, Levine M, Booker L, Oremus M. 2008. Effectiveness of cholinesterase inhibitors and memantine for treating dementia: evidence review for a clinical practice guideline. Ann. Intern. Med. 148: 379-397.
37. Robert PH, Allain H. 2001. Clinical management of agitation in the elderly with tiapride. Eur. Psychiatry 16(Suppl 1): 42s-47s.
38. Somani SM, Dube SN. 1989. Physostigmine--an overview as pretreatment drug for organophosphate intoxication. Int. J. Clin. Pharmacol. Ther. Toxicol. 27: 367-387.
39. Teiwes J, Toto RD. 2007. Epithelial sodium channel inhibition in cardiovascular disease. A potential role for amiloride. Am. J. Hypertens. 20: 109-117.
40. Thiermann H, Szinicz L, Eyer P, Felgenhauer N, Zilker T, Worek F. 2007. Lessons to be learnt from organophosphorus pesticide poisoning for the treatment of nerve agent poisoning. Toxicology 233: 145-154.
41. Triggle DJ, Mitchell JM, Filler R. 1998. The pharmacology of physostigmine. CNS Drug Rev. 4: 87-136.
42. Tuovinen K, Kaliste-Korhonen E, Raushel FM, Hanninen O. 1999. Success of pyridostigmine, physostigmine, eptastigmine and phosphotriesterase treatments in acute sarin intoxication. Toxicology 134: 169-178.
43. Watson A, Bakshi K, Opresko D, Young R, Hauschild V, King J. 2006. Cholinesterase inhibitors as chemical warfare agents: Community preparedness guidelines. In Toxicology of Organophosphate and Carbamate Compounds, Gupta RC (ed.). Elsevier Academic Press: Amsterdam; 47-68.
44. Wiener SW, Hoffman RS. 2004. Nerve agents: a comprehensive review. J. Intensive Care Med. 19: 22-37.
45. Worek F, Thiermann H, Szinicz L, Eyer P. 2004. Kinetic analysis of interactions between human acetylcholinesterase, structurally different organophosphorus compounds and oximes. Biochem. Pharmacol. 68: 2237-2248.
46. Xia DY, Wang LX, Pei SQ. 1981. The inhibition and protection of cholinesterase by physostigmine and pyridostigmine against Soman poisoning in vivo. Fundam. Appl. Toxicol. 1: 217-221.
47. Zhao B, Moochhala SM, Tham SY. 2004. Biologically active components of Physostigma venenosum. J. Chromatogr. B Analyt. Technol. Biomed. Life Sci. 812: 183-192.